BSE Live
Aug 16, 16:00Prev. Close
0.51
Open Price
0.51
Bid Price (Qty.)
0.51 (100)
Offer Price (Qty.)
0.00 (0)
NSE Live
Dec 27, 11:22Prev. Close
-
Open Price
-
Bid Price (Qty.)
- (0)
Offer Price (Qty.)
- (0)
| Cash Flow of Vardhman Lab (in Rs. Cr.) | Mar 18 | Mar 18 | Mar 17 | Mar 16 | Mar 15 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| Net Profit/Loss Before Extraordinary Items And Tax | 0.00 | 0.00 | 0.00 | -0.03 | -0.03 | |
| Net CashFlow From Operating Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.31 | |
| Net Cash Used In Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Cash Used From Financing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Foreign Exchange Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Adjustments On Amalgamation Merger Demerger Others | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Inc/Dec In Cash And Cash Equivalents | 0.00 | 0.00 | 0.00 | 0.00 | 0.31 | |
| Cash And Cash Equivalents Begin of Year | 0.00 | 0.00 | 0.00 | 0.54 | 0.23 | |
| Cash And Cash Equivalents End Of Year | 0.00 | 0.00 | 0.00 | 0.53 | 0.54 |
19.03.2026
19.03.2026
18.03.2026
18.03.2026
MFs boost healthcare exposure, turn overweight on earnings recovery and valuations
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth